Senior Correspondent, London
Ben's Feed
Feb 6, 2015
Feb 5, 2015
Feb 5, 2015

AstraZeneca to buy Actavis lung drugs as Q4 earnings fall short

LONDON, Feb 5 (Reuters) – AstraZeneca has agreed to
buy Actavis’ branded respiratory drug business in the
United States and Canada for an initial $600 million as it seeks
external deals to ensure growth.

AstraZeneca will also pay another $100 million, after
Actavis agreed to a number of changes to ongoing agreements
between the two firms.

Feb 5, 2015
Feb 4, 2015

GSK gives roadmap for potential 2016 listing of HIV drugs business

LONDON (Reuters) – GlaxoSmithKline (GSK.L: Quote, Profile, Research) set out a roadmap for a potential 2016 flotation of its HIV medicines business on Wednesday as it hired three leading banks to advise on what would be the drug industry’s largest ever initial public share sale.

Chief Executive Andrew Witty said his company would take the next two to three months to analyze the pros and cons of an initial public offering (IPO), as well as deciding how much of ViiV to sell and where to list the shares.

Feb 4, 2015

GlaxoSmithKline sees better signs for lung drugs after tough 2014

LONDON, Feb 4 (Reuters) – GlaxoSmithKline expects to
start regaining market share in respiratory medicine after weak
demand for lung drug Advair again hurt fourth-quarter sales,
capping a rough year for Britain’s top drugmaker.

GSK is also banking on an asset swap with Novartis
to help revive its fortunes, and looking to unlock value by
floating its HIV unit ViiV Healthcare. It has hired three banks
to advise on ViiV options, according to people familiar with the
matter.

Feb 3, 2015
Feb 1, 2015
Feb 1, 2015
Feb 1, 2015

Analysis: In pursuit of next-generation Ebola stockpile vaccines

LONDON (Reuters) – As West Africa’s devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.

Determined not to lose scientific momentum that could make the world’s first effective Ebola interventions a reality, researchers say the shots, as well as being proven to work, must be cheap, easy to handle in Africa and able to hit multiple virus strains.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben